GHK-Cu Falls With Age. The One Human Skin Trial Found Nothing.

Draw blood from a twenty-year-old and a sixty-year-old and run it through a peptide assay, and you’ll find a real difference: the older sample carries less than half as much of a specific copper-binding molecule as the younger one does. That molecule is GHK-Cu, a small copper-carrying peptide the body produces naturally, and its levels fall from around 200 nanograms per millilitre at age 20 to about 80 by age 60.

That’s one of the cleaner age-correlated biomarkers on record, and it comes with a mechanism story that sounds almost too good. Restore the peptide, the theory goes, and you might nudge some of the gene programs that go quiet with age back on. Then someone actually tested that story on human skin. The one published randomised, placebo-controlled trial came back indistinguishable from placebo on every objective measure.

So which is true? A real biological lever nobody’s figured out how to pull yet, or a compound whose best evidence lives entirely in test tubes and rat wounds?

What GHK-Cu actually is

GHK is three amino acids strung together: glycine, histidine, lysine. Researchers Pickart, Thaler and Millard documented it binding copper in human plasma in a 1979 paper, and that pairing turned out to matter more than the tripeptide alone. One of those amino acids grips a copper ion tightly enough that the copper-loaded form, not the bare peptide, is what does the actual work in nearly every study. Strip the copper off and the molecule is a different, weaker thing.

Does GHK-Cu reprogram aging gene expression, or is that a stretch?

The biggest published review on this compound, Pickart and Margolina’s 2018 paper in the International Journal of Molecular Sciences, makes a real case. It describes GHK-Cu shifting gene-expression programs in skin, blood vessel, and nerve tissue toward the repair side of the ledger rather than the breakdown side. That’s peer-reviewed, published work.

Here’s the stretch: does the age-related drop in plasma GHK cause those programs to quiet down, and would putting the peptide back reverse it? Nobody has shown that. The correlation between falling GHK and getting older is solid. The idea that low peptide causes tissue dysfunction, and that restoring it undoes the dysfunction, is still just a hypothesis. A good one. Still a hypothesis.

The wound-healing evidence

In cell culture and in animal wound models, the copper-bound complex does a genuinely long list of things. It nudges cells to build more of the structural proteins that hold skin together. It tips the balance inside healing tissue toward building and repairing, rather than breaking down. It also gets new blood vessels growing at the injury site. It also acts as an antioxidant, the copper it carries does the work, neutralizing the kind of chemical damage that piles up in aging tissue. Every one of those findings is documented, and all of them come from cell culture and animals.

That’s worth sitting with for a second. Pickart co-authored the 1979 paper that first flagged the copper, and forty years later he’s still a co-author on the review making the biggest claims for the compound. Either the case is solid enough that nobody else needed to check it twice, or not enough people have been checking.

Can enough GHK-Cu penetrate skin to reach the cells that matter?

Here’s the part that actually decides whether any of this matters for a cream you rub on your face. Skin’s outer layer exists specifically to keep small charged molecules like this one out. GHK-Cu is small, charged, and carrying a copper ion. That’s close to a checklist of properties that make skin penetration hard.

Does enough of it cross that barrier to reach the fibroblasts living underneath, at a concentration that would trigger the gene-expression effects seen in a dish? The honest answer is nobody’s published the data to say yes. Nobody has published data confirming that enough of the compound, whether the plain version or the modified form sold in most creams, actually crosses the skin barrier to reach the cells it’s supposed to affect. That’s not a small caveat. For a topical product, it’s the whole question.

What the human trials actually show

The human record on GHK-Cu skin products is thin: a handful of small trials, several of them uncontrolled or run by the company selling the cream. Only one meets the bar of a proper randomised, placebo-controlled design measuring objective outcomes instead of how a panel of testers felt their skin looked. That trial found GHK-Cu indistinguishable from placebo.

Does that mean the mechanism is wrong? Nobody knows. It could mean the mechanism doesn’t carry over to human skin the way it does in a dish. It could mean the topical dose tested was too low, or the formulation failed to deliver the peptide where it needed to go. Or a single trial simply wasn’t powered to catch a real but modest effect. The study that would tell us which of those is true, one that pairs a measured skin-penetration rate with a clinical outcome, hasn’t been run. Calling the negative result a delivery failure, without that study, is a guess wearing an explanation’s clothes.

Injectable vs. topical: does the route change the answer?

There’s a regulatory wrinkle that maps onto this exact question. GHK-Cu wasn’t on the FDA’s first Pharmacy Compounding Advisory Committee docket, the one that met in July 2026. It’s scheduled for the agency’s second meeting, expected before the end of February 2027, and when it gets there, the FDA is treating the two routes as separate questions. Injectable GHK-Cu came off the agency’s do-not-compound list. Topical GHK-Cu, which had been sitting on a provisional allowed list while the agency made up its mind, lost even that temporary standing. Same molecule, opposite regulatory direction, split entirely by route.

That split doesn’t tell us whether an injection outperforms a cream. It does tell us the two are being treated as genuinely different products, not two names for the same thing. An injection skips the skin-barrier problem entirely: it puts the peptide straight into the bloodstream, removing the whole penetration question a cream has to solve. Whether that turns into a different result in actual human tissue is a question nobody has tested.

Reading a GHK-Cu label

The phrase copper peptides on a label can mean plain GHK-Cu, the fat-modified version, or a proprietary blend that doesn’t say which. Those aren’t interchangeable, and the thin penetration and stability data doesn’t automatically transfer from one to the other. A brand that cites a lab study as proof its finished cream works is borrowing a scientist’s good name to cover a product nobody has actually tested on people.

None of that makes the compound worthless. It makes the honest claim a narrow one: a real, measurable decline with age, a plausible and well-documented mechanism in cells and animals, and one disappointing human skin trial that nobody has yet explained. A label promising more than that is selling the review, not the cream.

What we actually know

Three things are true at once here. The age-related drop in plasma GHK-Cu is real and measurable. The preclinical case for what the copper-bound peptide does to tissue is stronger than most peptides get. And the one human trial that actually tested it on skin came back no different from placebo. None of those facts cancels out the others.

What’s missing is the study that explains why: not enough peptide crossing the skin, not enough peptide in the formulation, or a mechanism that simply doesn’t carry over from a dish to a face. Until that study exists, three explanations are still on the table. If you’re buying a GHK-Cu cream today, you’re betting ahead of the proof, and you’re betting the same way the people selling it are: that the mechanism is real and the first trial just got the delivery wrong. That might be right. Nobody knows yet.